ITMI20120117A1 - COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. - Google Patents
COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. Download PDFInfo
- Publication number
- ITMI20120117A1 ITMI20120117A1 IT000117A ITMI20120117A ITMI20120117A1 IT MI20120117 A1 ITMI20120117 A1 IT MI20120117A1 IT 000117 A IT000117 A IT 000117A IT MI20120117 A ITMI20120117 A IT MI20120117A IT MI20120117 A1 ITMI20120117 A1 IT MI20120117A1
- Authority
- IT
- Italy
- Prior art keywords
- composition
- composition according
- base cream
- effective amount
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 55
- 238000011282 treatment Methods 0.000 title claims description 14
- 208000017520 skin disease Diseases 0.000 title claims description 13
- 239000006071 cream Substances 0.000 claims description 20
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 241000241037 Asphodelus ramosus Species 0.000 claims description 9
- 244000166124 Eucalyptus globulus Species 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 241000244950 Asphodelus Species 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 235000000458 Asphodeline lutea Nutrition 0.000 description 1
- 241001226615 Asphodelus albus Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
DESCRIZIONE DESCRIPTION
“Composizione per il trattamento delle malattie della pelle†⠀ œComposition for the treatment of skin diseasesâ €
Campo deH’invenzione Field of invention
La presente invenzione si riferisce ad una composizione per il trattamento delle malattie della pelle. In particolare, si riferisce ad una composizione per il trattamento della psoriasi e dei reumatismi. The present invention relates to a composition for the treatment of skin diseases. In particular, it refers to a composition for the treatment of psoriasis and rheumatism.
Stato dell’ arte. State of the art.
La pelle à ̈ il più grande organo del corpo umano che svolge diverse funzioni come la protezione, barriera, controllo della temperatura, escrezione e respirazione. The skin is the largest organ in the human body that performs various functions such as protection, barrier, temperature control, excretion and respiration.
Tuttavia, la pelle à ̈ soggetta a varie malattie come, ad esempio, la psoriasi, eczema, dermatite seborroica, acne, herpes labiale, ed arrossamenti di ogni tipo. However, the skin is subject to various diseases such as, for example, psoriasis, eczema, seborrheic dermatitis, acne, cold sores, and redness of all kinds.
La psoriasi à ̈ una delle più comuni forme croniche di malattia della pelle nel mondo. Essa viene riscontrata nel 1-2% della popolazione generale, nel 2% della popolazione della Gran Bretagna, nel 2,6% della popolazione USA e in percentuali minori nei paesi dell’Africa occidentale e del Giappone. È una malattia infiammatoria della pelle, non infettiva, solitamente di carattere cronico e recidivante; per questo motivo un soggetto affetto da psoriasi non sarà mai completamente guarito, ma avrà momenti in cui gli effetti della malattia sono meno incisivi. Psoriasis is one of the most common chronic forms of skin disease in the world. It is found in 1-2% of the general population, in 2% of the population of Great Britain, in 2.6% of the US population and in smaller percentages in the countries of West Africa and Japan. It is a non-infectious inflammatory skin disease, usually chronic and relapsing; for this reason a person suffering from psoriasis will never be completely cured, but will have moments when the effects of the disease are less effective.
Nel caso di forme generalizzate di psoriasi, a volte si ricorre a terapie sistemiche. Queste includono fototerapia con UVB, oppure con UVA e psoraleni (fotochemioterapia o PUVA terapia). Possono essere utilizzati anche retinoidi (acitretina ed etretinato), o ciclosporina A. In the case of generalized forms of psoriasis, systemic therapies are sometimes used. These include phototherapy with UVB, or with UVA and psoralens (photochemotherapy or PUVA therapy). Retinoids (acitretin and etretinate), or cyclosporine A can also be used.
Da un’analisi compiuta recentemente sui risultati delle terapie sistemiche in caso di psoriasi a placche severa, sembra che i migliori risultati siano ottenuti con la fotochemioterapia, seguita dal trattamento UVB e poi dagli altri trattamenti. From a recent analysis of the results of systemic therapies in severe plaque psoriasis, it seems that the best results are obtained with photochemotherapy, followed by UVB treatment and then by other treatments.
Tuttavia, gli effetti collaterali sono particolarmente frequenti con l’utilizzo dei retinoidi, e sono soprattutto di carattere muco-cutaneo. Tutti questi trattamenti, in particolare quelli sistemici, comportano certi rischi di tossicità , in quanto il rischio di insorgenza di tumori cutanei aumenta nei soggetti sottoposti a tale terapia. Trattamenti con derivati della vitamina A (retinolo) vanno utilizzati solo in ambienti altamente specializzati e sotto stretto controllo medico. However, side effects are particularly frequent with the use of retinoids, and are mainly of a mucocutaneous character. All these treatments, in particular the systemic ones, involve certain risks of toxicity, as the risk of the onset of skin tumors increases in subjects undergoing such therapy. Treatments with derivatives of vitamin A (retinol) should only be used in highly specialized environments and under strict medical supervision.
La Richiedente ha notato che particolari composizioni danno effetti benefici per la cura della psoriasi, dei reumatismi e di altre malattie della pelle, senza indesiderati effetti collaterali. The Applicant has noted that particular compositions give beneficial effects for the treatment of psoriasis, rheumatism and other skin diseases, without unwanted side effects.
Sommario dell’ invenzione Summary of the invention
Pertanto, in un primo aspetto la presente invenzione si riferisce ad una composizione come quella indicata nella rivendicazione 1. Therefore, in a first aspect the present invention refers to a composition such as that indicated in claim 1.
La Richiedente della presente domanda ha infatti sorprendentemente riscontrato che una composizione per il trattamento delle malattie della pelle comprendente: The Applicant of the present application has in fact surprisingly found that a composition for the treatment of skin diseases comprising:
- una quantità efficace di un estratto da una porzione di radice di una pianta di Asphodelus Microcarpus, ed - an effective amount of an extract from a root portion of an Asphodelus Microcarpus plant, and
- una quantità efficace di una crema di base avente un pH compreso tra 5,0 e 7,0, à ̈ una composizione atta a trattare le malattie della pelle umana ed animale, in particolare atta a trattare la psoriasi, arrossamenti e reumatismi. - an effective amount of a base cream having a pH between 5.0 and 7.0, it is a composition suitable for treating human and animal skin diseases, in particular for treating psoriasis, redness and rheumatism.
Infatti, per mezzo dell’applicazione della composizione della presente invenzione à ̈ stato riscontrato un particolare beneficio da parte di pazienti affetti da psoriasi e/o da reumatismi, senza indurre al tempo stesso né effetti collaterali indesiderati, né tossicità . In fact, by means of the application of the composition of the present invention, a particular benefit has been found on the part of patients suffering from psoriasis and / or rheumatism, without inducing at the same time neither unwanted side effects nor toxicity.
L' Asphodelus Microcarpus (detto anche Asfodelo Mediterraneo) à ̈ una pianta della famiglia delle Liliacee, che conta più di cento specie e proviene dalle zone a clima temperato in particolare del bacino mediterraneo. The Asphodelus Microcarpus (also called Mediterranean Asphodel) is a plant of the Liliacee family, which has more than one hundred species and comes from the temperate climate areas, in particular the Mediterranean basin.
Preferibilmente, detto pH della crema di base à ̈ compreso tra 5,5 e 6,5. Preferably, said pH of the base cream is between 5.5 and 6.5.
In questo modo si ottiene una migliore stabilità della crema di base e, di conseguenza, della composizione della presente invenzione. In this way a better stability of the base cream and, consequently, of the composition of the present invention is obtained.
Preferibilmente, nella composizione secondo la presente invenzione detta quantità efficace di radice di Asphodelus à ̈ tra 10% e 30%, più preferibilmente tra 15% e 25%, e detta quantità efficace di detta crema di base à ̈ tra 70% e 90%, più preferibilmente tra 75% e 85%, dove dette percentuali sono intese in peso rispetto al peso totale di detta composizione. Preferably, in the composition according to the present invention said effective amount of Asphodelus root is between 10% and 30%, more preferably between 15% and 25%, and said effective amount of said base cream is between 70% and 90% , more preferably between 75% and 85%, where said percentages are intended by weight with respect to the total weight of said composition.
Preferibilmente, detta crema di base comprende almeno un tensioattivo scelto tra il gruppo che comprende acidi caibossilici salificati aventi almeno 12 atomi di carbonio ed eteri di poliossietilene di una miscela di alcol grassi saturi. Preferably, said base cream comprises at least one surfactant selected from the group comprising salified caiboxylic acids having at least 12 carbon atoms and polyoxyethylene ethers of a mixture of saturated fatty alcohols.
Esempi utili di tensioattivi del tipo appartenenti alla classe degli acidi carbossilici salificati aventi almeno 12 atomi di carbonio comprendono, ad esempio, acido paimitico, acido stearico, acido oleico salificati ad esempio con trietanolammina (TEA). Più preferibilmente, la composizione della presente invenzione comprende acido stearico salificato con trietanolammina, come tensioattivo. Useful examples of surfactants of the type belonging to the class of salified carboxylic acids having at least 12 carbon atoms include, for example, paimitic acid, stearic acid, oleic acid salified for example with triethanolamine (TEA). More preferably, the composition of the present invention comprises salified stearic acid with triethanolamine as the surfactant.
Preferibilmente, tensioattivi del tipo appartenenti alla classe degli eteri di poliossietilene di una miscela di alcol grassi saturi sono i composti denominati Ceteareth-n, aventi formula C3⁄4 - (CH2)m- (0-CH2-CH2)n- OH, dove m à ̈ l5 o l7 ed n à ̈ varaibile da 2 a 100. Particolarmente preferito à ̈ il composto denominato Ceteareth-25. Preferably, surfactants of the type belonging to the class of polyoxyethylene ethers of a mixture of saturated fatty alcohols are the compounds called Ceteareth-n, having formula C3⁄4 - (CH2) m- (0-CH2-CH2) n- OH, where m is l5 or l7 and n is variable from 2 to 100. Particularly preferred is the compound called Ceteareth-25.
Preferibilmente, detta composizione per il trattamento delle malattie della pelle comprende inoltre uno sciroppo a base di una miscela di alcol e di foglie della pianta di eucalipto. Più preferibilmente, detta composizione comprende: a) tra 10% e 30% di detta radice di Asphodelus, b) tra 70% e 90% di detta crema di base, c) tra 1% e 10% di uno sciroppo a base di alcol e d) tra 0,1% e 5% di foglie della pianta di eucalipto, dove dette percentuali sono intese in peso rispetto al peso totale di detta composizione. Ancora più preferibilmente, detta composizione comprende: a) tra 15% e 25% di detta radice di Asphodelus, b) tra 75% e 85% di detta crema di base, c) tra 2% e 5% di uno sciroppo a base di alcol e d) tra 0,2% e 3% di foglie della pianta di eucalipto, dove dette percentuali sono intese in peso rispetto al peso totale di detta composizione. Preferably, said composition for the treatment of skin diseases further comprises a syrup based on a mixture of alcohol and leaves of the eucalyptus plant. More preferably, said composition comprises: a) between 10% and 30% of said Asphodelus root, b) between 70% and 90% of said base cream, c) between 1% and 10% of an alcohol-based syrup and d) between 0.1% and 5% of leaves of the eucalyptus plant, wherein said percentages are intended by weight with respect to the total weight of said composition. Even more preferably, said composition comprises: a) between 15% and 25% of said Asphodelus root, b) between 75% and 85% of said base cream, c) between 2% and 5% of a syrup based on alcohol and d) between 0.2% and 3% of leaves of the eucalyptus plant, where said percentages are intended by weight with respect to the total weight of said composition.
In questo modo, la composizione secondo la presente invenzione à ̈ in grado di curare altre malattie della pelle, oltre alla psoriasi, come ad esempio acne, herpes labiale, eczemi, dermatite seborroica, e punture di zanzare. In this way, the composition according to the present invention is able to treat other skin diseases, in addition to psoriasis, such as acne, cold sores, eczema, seborrheic dermatitis, and mosquito bites.
Preferibilmente, la composizione secondo la presente invenzione à ̈ nella forma di crema, pomata, unguento, gel, latte, lozione, od altre forme tipiche usate in cosmesi e/o dermatologia. Preferably, the composition according to the present invention is in the form of cream, ointment, ointment, gel, milk, lotion, or other typical forms used in cosmetics and / or dermatology.
Più preferibilmente, la composizione secondo la presente invenzione à ̈ nella forma di crema morbida, non untuosa. Va applicata sulla pelle, spargendola in modo uniforme, e ripetendo l’operazione anche più volte al giorno. More preferably, the composition according to the present invention is in the form of a soft, non-greasy cream. It should be applied on the skin, spreading it evenly, and repeating the operation several times a day.
In un secondo aspetto la presente invenzione si riferisce all’uso di una composizione sopra descritta come quello indicato nella rivendicazione 10. In a second aspect the present invention relates to the use of a composition described above such as that indicated in claim 10.
La Richiedente della presente domanda ha infatti sorprendentemente riscontrato che una composizione cosmetica e/o dermatologica come quella sopra descritta può essere utilizzata per trattare le malattie della pelle sopra riportate, in particolare per trattare la psoriasi. The Applicant of the present application has in fact surprisingly found that a cosmetic and / or dermatological composition such as the one described above can be used to treat the above mentioned skin diseases, in particular to treat psoriasis.
Ulteriori caratteristiche e vantaggi del presente ritrovato risulteranno meglio evidenziati dall’esame della seguente descrizione dettagliata di una forma di realizzazione preferita, ma non esclusiva, illustrata a titolo indicativo e non limitativo. Descrizione detagliata. Further characteristics and advantages of the present invention will be better highlighted by examining the following detailed description of a preferred but not exclusive embodiment, illustrated by way of non-limiting example. Detailed description.
La descrizione dettagliata seguente si riferisce ad una forma particolare di realizzazione di una composizione secondo la presente invenzione. The following detailed description refers to a particular embodiment of a composition according to the present invention.
Esempi. Examples.
Preparazione di succo di Asphodelus Microcarpus. Preparation of Asphodelus Microcarpus juice.
Furono prese delle radici da una pianta di Asphodelus Microcarpus aventi pH pari a circa 5,5, furono lavate e tritate in un contenitore di acciaio, fino ad ottenere un succo SI di tali radici conservato al fresco. Roots were taken from an Asphodelus Microcarpus plant with a pH of about 5.5, washed and ground in a steel container until a cool-preserved SI juice of these roots was obtained.
Preparazione di sciroppo a base di foglie di Eucalipto. Preparation of syrup based on Eucalyptus leaves.
Furono prese delle foglie da una pianta di eucalipto, furono lavate ed inserite in un contenitore di acciaio, aggiungendo alcol per 4 settimane fino ad ottenere uno sciroppo S2. Leaves were taken from a eucalyptus plant, washed and placed in a steel container, adding alcohol for 4 weeks until an S2 syrup was obtained.
Composizione 1 (<'>invenzione<'>). Composition 1 (<'> invention <'>).
Furono presi 200 grammi del succo SI ottenuto dalle radici di Asphodelus Microcarpus e miscelati con 1 Kg di una crema di base idrofila, denominata “Crema di base idrofila†e disponibile in commercio tramite la Azienda Chimica e Farmaceutica (ACEF) con il codice 6413. Tale crema di base ha un pH pari a 6,15 e comprende, tra i vari ingredienti, i tensioattivi Ceteareth-25 e trietanolammina (TEA) stearato. Alla fine della miscelazione si ottenne la composizione 1 della presente invenzione. 200 grams of the SI juice obtained from the roots of Asphodelus Microcarpus were taken and mixed with 1 kg of a hydrophilic base cream, called â € œHydrophilic base creamâ € and commercially available through the Chemical and Pharmaceutical Company (ACEF) with the code 6413 This base cream has a pH of 6.15 and includes, among the various ingredients, the surfactants Ceteareth-25 and triethanolamine (TEA) stearate. At the end of the mixing, the composition 1 of the present invention was obtained.
La composizione 1 dell’invenzione così preparata si presentava sotto forma di crema morbida e venne testata, somministrandola per alcuni giorni a 10 pazienti, 5 maschi e 5 femmine, di età variabile tra i 20 ed i 60 anni, affetti da psoriasi al fine di valutarne l’utilizzo. Composition 1 of the invention thus prepared was presented in the form of a soft cream and was tested by administering it for a few days to 10 patients, 5 males and 5 females, aged between 20 and 60 years, suffering from psoriasis at the in order to evaluate its use.
Dopo 1-2 giorni dall’inizio della somministrazione della Composizione 1, tutti i pazienti mostrarono i primi risultati benefici, con una sensibile riduzione del prurito. After 1-2 days from the beginning of the administration of Composition 1, all patients showed the first beneficial results, with a significant reduction in itching.
Continuando a somministrare la Composizione 1, dopo si ottenere circa 2- 3 mesi si notarono dei miglioramenti significativi nei pazienti affetti da psoriasi, senza la presenza di alcun effetto collaterale. Continuing to administer Composition 1, after about 2 to 3 months, significant improvements were noted in patients suffering from psoriasis, without the presence of any side effects.
Composizione 2 (<'>invenzione^ Composition 2 (<'> invention ^
Alla composizione 1 furono aggiunti 4 grammi di sciroppo S2 ottenuto dalle foglie di eucalipto. Alla fine della miscelazione si ottenne la composizione 2 della presente invenzione. 4 grams of S2 syrup obtained from eucalyptus leaves were added to composition 1. At the end of the mixing, the composition 2 of the present invention was obtained.
La composizione 2 deH’invenzione cosi preparata si presentava sotto forma di crema morbida e venne testata, somministrandola per alcuni giorni ad un numero di pazienti affetti da malattie della pelle, come psoriasi, eczema, dermatite seborroica, herpes, bruciature della pelle fino al 4° grado, ed anche reumatismi, al fine di valutarne Γ utilizzo. The composition 2 of the invention thus prepared was presented in the form of a soft cream and was tested by administering it for a few days to a number of patients suffering from skin diseases, such as psoriasis, eczema, seborrheic dermatitis, herpes, skin burns up to 4th degree, and also rheumatism, in order to evaluate its use.
Dopo solo 1 settimana si notarono dei miglioramenti nei pazienti affetti da herpes; dopo 2 mesi si notarono dei miglioramenti anche nei pazienti affetti da reumatismi, eczema, dermatite seborroica e bruciature della pelle, mentre dopo circa 2-3 mesi si notarono dei miglioramenti significativi perfino nei pazienti affetti da psoriasi, senza effetti collaterali. After only 1 week improvements were noted in herpes patients; after 2 months improvements were also noted in patients suffering from rheumatism, eczema, seborrheic dermatitis and skin burns, while after about 2-3 months significant improvements were noted even in patients with psoriasis, without side effects.
Dagli esempi sopra riportati risulta quindi evidente che le composizioni della presente invenzione permisero di ottenere dei benefici nel trattamento delle malattie della pelle. From the above examples it is therefore evident that the compositions of the present invention made it possible to obtain benefits in the treatment of skin diseases.
Naturalmente, alle persone esperte nel ramo saranno evidenti molte modifiche e varianti delle forme di realizzazione preferite descritte, rimanendo ancora all'interno dell'ambito dell'invenzione. Of course, many modifications and variations of the described preferred embodiments will be apparent to those skilled in the art, still remaining within the scope of the invention.
Pertanto, l'invenzione non à ̈ limitata alle forme preferite di realizzazione descritte, illustrate solo a scopo esemplificativo e non limitativo, ma à ̈ definita dalle rivendicazioni che seguono. Therefore, the invention is not limited to the preferred embodiments described, illustrated only by way of non-limiting example, but is defined by the following claims.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000117A ITMI20120117A1 (en) | 2012-01-31 | 2012-01-31 | COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000117A ITMI20120117A1 (en) | 2012-01-31 | 2012-01-31 | COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20120117A1 true ITMI20120117A1 (en) | 2013-08-01 |
Family
ID=45998491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000117A ITMI20120117A1 (en) | 2012-01-31 | 2012-01-31 | COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITMI20120117A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1166791A2 (en) * | 1996-03-22 | 2002-01-02 | Said Moady | Antipsoriatic compositions comprising an asphodelus extract, method of making, and method of using |
-
2012
- 2012-01-31 IT IT000117A patent/ITMI20120117A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1166791A2 (en) * | 1996-03-22 | 2002-01-02 | Said Moady | Antipsoriatic compositions comprising an asphodelus extract, method of making, and method of using |
Non-Patent Citations (3)
| Title |
|---|
| ALI-SHTAYEH M S ET AL: "ANTIFUNGAL ACTIVITY OF PLANT EXTRACTS AGAINST DERMATOPHYTES//ANTIMYZETISCHE AKTIVITAET VON PFLANZENEXTRAKTEN GEGEN DERMATOPHYTEN", MYCOSES, BLACKWELL, BERLIN, DE, vol. 42, no. 11/12, 1 December 1999 (1999-12-01), pages 665 - 672, XP001182623, ISSN: 0933-7407, DOI: 10.1046/J.1439-0507.1999.00499.X * |
| RIMBAU V ET AL: "Antiinflammatory activity of some extracts from plants used in the traditional medicine of North-African countries", PHYTOTHERAPY RESEARCH, vol. 10, no. 5, 1996, pages 421 - 423, XP002680217 * |
| SAID O ET AL: "Ethnopharmacological survey of medicinal herbs in Israel, the Golan Heights and the West Bank region", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 83, no. 3, 1 December 2002 (2002-12-01), pages 251 - 265, XP009151222, ISSN: 0378-8741, [retrieved on 20021101], DOI: 10.1016/S0378-8741(02)00253-2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008140200A1 (en) | External compositions for the skin | |
| KR101514970B1 (en) | Cmposition for treating or preventing atopic dermatitis or skin wound comprising phytosphingosine-1-phosphate or its derivatives | |
| ES2358925T3 (en) | ANTI-INFLAMMATORY COMPOSITIONS AND USE PROCEDURES. | |
| JP5284093B2 (en) | Anti-inflammatory compositions and methods of use | |
| EP2700413B1 (en) | Composition comprising dihydroquercetin, alpha-tocopherol and bisabolol | |
| JPS6330884B2 (en) | ||
| US9572777B2 (en) | Topical pharmaceutical composition comprising nanonized silver sulfadiazine | |
| US20230270807A1 (en) | Antimicrobial compositions | |
| US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| TW201605444A (en) | Topical pharmaceutical or cosmetic compositions comprising octenidine dihydrochloride | |
| US20150238462A1 (en) | Composition comprising plant phenols for preventing or reducing tewl and associated disorders and diseases | |
| EP2983684B1 (en) | Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations | |
| ES2379474T3 (en) | Dermatological product for the treatment and / or skin care with neurodermitis | |
| KR20140092205A (en) | Pharmaceutical composition containing catechin or its derivatives for prevention or treatment of disorders of follicular keratinization | |
| ITMI20120117A1 (en) | COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. | |
| ITMI20120118A1 (en) | COMPOSITION FOR THE TREATMENT OF SKIN DISEASES. | |
| KR20170065187A (en) | Cosmetic composition for improving acne containing tea-tree leaves complex extract | |
| WO2013154806A1 (en) | Herbal composition and a method of making thereof | |
| JP6002510B2 (en) | Estrogen receptor β activator | |
| EP3796897B1 (en) | Compounds for preventing and treating skin or mucosal affections having an inflammatory component | |
| JP6671832B2 (en) | Heat shock protein expression inducer | |
| JP2014144929A (en) | Composition containing vitamins for preventing or treating acne | |
| US11633425B2 (en) | Anti-glycation compositions | |
| RU2559151C2 (en) | Method of treating demodectic blepharoconjunctivitis | |
| US20190175601A1 (en) | Composition for inhibiting or alleviating itching including riboflavin |